|
COPYRIGHT 2006 Asia Pulse Pty Ltd
(Full text of a statement. Contact details below.)
NEW YORK--(BUSINESS WIRE)--Sept.
29, 2006--OMRIX Biopharmaceuticals, Inc.
("OMRIX" or the "Company") (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, today announced two new strategic product development programs in anti adhesion and spine utilizing its fibrin sealant technology.
Development milestones include the submission of an IND/IDE (Investigational New Drug/Investigational Device Exemption) submission in December 2006...
Read the full article for free courtesy of your local library.
|